United Therapeutics Corporation
United Therapeutics Reports Record Q2 2025 Financial Results and Authorizes $1B Share Repurchase
Summary
United Therapeutics Corporation reported record financial results for the second quarter of 2025, with total revenues growing 12% year-over-year to $798.6 million, driven by strong performance in key products like Tyvaso DPI and Orenitram. The company also announced a share repurchase program of up to $1 billion authorized by the Board of Directors, effective until March 31, 2026. Management expects continued double-digit revenue growth and highlighted upcoming data from clinical trials that could improve treatment options for patients with pulmonary fibrosis and pulmonary hypertension.
Profitelligence Alerts
Get alerts for UTHR
Be first to know when United Therapeutics Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company engaged in the development and commercialization of innovative pharmaceutical products. Primarily focusing on therapies to address unmet medical needs for chronic and life-threatening conditions, United Therapeutics is notable for its contributions in the field of pulmonary arterial hypertension (PAH). The company offers a portfolio of products that include both oral and inhaled treatments, such as Remodulin and Tyvaso, providing critical care solutions that significantly improve patients' quality of life. Additionally, they are investing in innovative technologies such as organ manufacturing and regenerative medicine, showcasing a commitment to future medical advances. Headquartered in Silver Spring, Maryland, United Therapeutics operates across various stages of drug research, from clinical trials to post-market analysis. As a key player in the biotechnology industry, the company holds an influential position, contributing to significant advancements in therapeutic solutions and reinforcing its role in the healthcare market by addressing complex medical challenges and patient needs effectively.
Official SEC Documents
Advertisement